DexCom Inc (DXCM)

Industry Medical Devices
This stock can be held in an Investment ISA and an Investment Account
Sell

$80.00

Buy

$83.18

arrow-up$1.26 (+1.57%)

DexCom Inc designs, develops and commercializes continuous glucose monitoring systems for ambulatory use by people with diabetes and for use by healthcare providers in the hospital for the treatment of both diabetic and non-diabetic patients.
Prices updated at 07 May 2025, 00:51 EDT
| Prices minimum 15 mins delay
|
Prices in USD
NASDAQ
arrow-down-0.87%
NASDAQ
Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and
Our Investment Fees and Charges.
Sector
Healthcare
Industry
Medical Devices
Chairman
Mr. Kevin R. Sayer, C.P.A.
CEO
Mr. Kevin R. Sayer, C.P.A.
Most recent earnings
31 Dec 2024
Fiscal year end
31 Dec 2024
Employees
10,300
Head office
6340 Sequence Drive
San Diego
United States
92121
mobile
+1 858 200-0200
letter
investorrelations@dexcom.com
computer
Company website

Key personnel

Owner nameSalaryBonusAll other compensationTotal compensationRestricted stock award
Ms. Karen M. Dahut
Independent Director
---0.34m-
Ms. Renee D. Gala
Independent Director
-----
Mr. Kevin R. Sayer, C.P.A.
President, Chief Executive Officer and Chairman of the Board
1.16m--15.83m-
Mr. Mark G. Foletta
Lead Independent Director
---0.39m-
Professor Dr. Eric J. Topol, M.D.
Independent Director
---0.34m-
Mr. Steven R. Altman
Independent Director
---0.34m-
Mr. Nicholas Augustinos
Independent Director
---0.34m-
Ms. Bridgette P. Heller
Independent Director
---0.34m-
Mr. Jereme M. Sylvain
Executive Vice President, Chief Financial Officer and Principal Accounting Officer
0.61m--5.85m-
Mr. Richard A. Collins
Independent Director
---0.34m-
Mr. Jacob S. Leach
Executive Vice President and Chief Operating Officer
0.68m--5.92m-
Mr. Kyle Malady
Independent Director
---0.34m-
Ms. Sadie M. Stern
Executive Vice President and Chief Human Resources Officer
0.54m--4.91m-
Mr. Michael J. Brown
Executive Vice President and Chief Legal Officer
0.60m--4.96m-
Ms. Rimma Driscoll
Independent Director
---0.34m-

Top 5 shareholders

Owner nameNo. of sharesShare as % of port.Last changePortfolio % changeDate of portfolio% Total assets
Vanguard Group Inc46,530,0170.06303-904784-1.90742730 Apr 202511.87
BlackRock Inc39,599,6010.06232457499013.06221530 Apr 202510.10
State Street Corp16,686,2300.0512197580.11854930 Apr 20254.26
BlackRock Fund Advisors15,577,14510.075179804-30 Apr 20253.97
Capital Research and Management Company15,079,1664.40012-5816557-30 Apr 20253.85

Director dealings

DateActionNamePriceValueNo. of sharesHolding (%)Additional info
16 Dec 2024-Ms. Bridgette P. Heller76.8776,87023,349--
16 Dec 2024-Mr. Jereme M. Sylvain76.8757,19180,030--
16 Dec 2024-Mr. Jake Leach76.8757,191264,171--
16 Dec 2024-Ms. Sadie Stern76.8732,59370,768--
20 Nov 2024-Ms. Sadie Stern74.73318,27571,192--
15 Nov 2024-Mr. Jereme M. Sylvain75.51264,28580,774--
16 Sep 2024-Ms. Bridgette P. Heller70.0070,00024,349--
09 Sep 2024-Mr. Jereme M. Sylvain69.1551,58684,274--
09 Sep 2024-Mr. Jake Leach69.1551,586264,915--
09 Sep 2024-Ms. Sadie Stern69.1529,45875,451--
30 Aug 2024-Mr. Micheal Jon Brown70.0048,02065,636--
31 Jul 2024-Mr. Micheal Jon Brown69.5545,34766,249--
28 Jun 2024-Mr. Micheal Jon Brown114.2975,31766,901--
17 Jun 2024-Mr. Mark G. Foletta117.16259,15960,179--
18 Jun 2024-Mr. Mark G. Foletta117.2535,05656,398--
18 Jun 2024-Mr. Mark G. Foletta116.75351,06556,697--
17 Jun 2024-Mr. Mark G. Foletta117.7755,94259,704--
17 Jun 2024-Mr. Mark G. Foletta115.1880662,391--
14 Jun 2024-Ms. Bridgette P. Heller113.55113,55025,349--
10 Jun 2024-Mr. Jereme M. Sylvain115.0585,71384,948--
Please note that past performance is not a reliable indicator of future returns.


Important Information

Please note the value of investments can go down as well as up so you may get back less than you invested. This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to an authorised financial adviser. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and(3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.
© Copyright 2025 Morningstar. All rights reserved.